High dose chemotherapy followed by Autologous Stem Cell Transplant (Auto-SCT) is considered standard of care for most patients with Multiple Myeloma (MM) in the U.S. However, recent evidence suggests that diabetic patients with MM are less likely to receive Auto-SCT due to concerns for higher toxicity. We sought to determine the impact of diabetes on in-hospital outcomes of MM patients undergoing autoSCT. We queried the Nationwide Inpatient Sample (NIS) from the years 2009-2011 to identify all adult hospitalizations with MM and auto-SCT. Diabetic status was ascertained using ICD-9 diagnostic codes. Primary and secondary outcomes were in-hospital mortality and length of stay (LOS) or costs of hospitalization (COH) respectively. Univariate methods included chi-square test and t-test where appropriate. Multivariate analysis was done using Generalized Linear Mixed Models (GLMM) to account for clustering in the dataset. All p values were two sided and level of significance was chosen at 0.05. A total of 2868 (14,153 estimated) hospitalizations for MM related auto-SCT was identified, out of which 13% had diabetes. The mean age was 58 ± 8.7 years, 43% females and 67% whites. The overall in-patient mortality rate was 1.78% whereas mean LOS and COH was 17 days and $160,720 respectively. Diabetes did not impact inpatient mortality (1.31% vs. 1.85%; p 0.45), LOS (18 vs. 17.6 days; p 0.33) or COH ($160,665 vs. \$160,728; p 0.99). Similar results were seen on GLMM for in-hospital mortality (adjusted Odds Ratio, aOR 0.67; 95% CI 0.26-1.75; p 0.42) after adjusting for patient (age, sex, race, comorbidity, insurance status) and hospital characteristics (bedsize, location, teaching status). Our large U.S. population-based study suggests that diabetic patients with MM undergoing Auto-SCT have similar in-hospital outcomes compared to their nondiabetic counterparts. Future studies should explore the incidence of other treatment related complications in this population.

Disclosure

K. Siwakoti: None. S. Giri: None. V. Bhatt: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.